

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	244	564/84	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L2	436	564/86	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L3	658	514/602	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L4	400	514/604	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:04

## EAST Search History


Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	244	564/84	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L2	436	564/86	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L3	658	514/602	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:03
L4	400	514/604	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 09:04

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13	((("5756533") or ("5776971") or ("6046190") or ("6143788") or ("6150556") or ("6156768") or ("6391919"))).PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:32
L2	0	David.inv. and carnii.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38
L3	58	David.inv. and carini.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13	((("5756533") or ("5776971") or ("6046190") or ("6143788") or ("6150556") or ("6156768") or ("6391919")).PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:32
L2	0	David.inv. and carnii.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38
L3	58	David.inv. and carini.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/12/08 07:38



chain nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20 21 22 23 24 25 26 29 30

ring nodes :

17 33 34 35 36 37

chain bonds :

1-2 1-29 2-3 2-4 2-5 3-30 5-6 6-7 7-8 7-9 9-10 10-11 10-12 12-13 12-14 14-15 15-16  
15-18 16-17 18-19 18-20 19-26 20-21 21-22 22-23 22-24 22-25

ring bonds :

17-33 17-37 33-34 34-35 35-36 36-37

exact/norm bonds :

2-4 2-5 5-6 7-8 7-9 9-10 10-11 12-13 12-14 14-15 18-19 20-21 21-22 22-23 22-24 22-25

exact bonds :

1-2 1-29 2-3 3-30 6-7 10-12 15-16 15-18 16-17 18-20 19-26

normalized bonds :

17-33 17-37 33-34 34-35 35-36 36-37

isolated ring systems :

containing 17 :

Match level :

1:CLASS2:CLASS3:CLASS4:Atom 5:CLASS6:CLASS7:CLASS8:CLASS9:CLASS10:CLASS11:CLASS  
12:CLASS13:CLASS14:CLASS15:CLASS16:CLASS17:Atom 18:CLASS19:CLASS20:CLASS21:CLASS  
22:CLASS23:CLASS24:CLASS25:Atom 26:CLASS29:CLASS30:CLASS33:Atom 34:Atom 35:Atom  
36:Atom 37:Atom

Generic attributes :

4:

Saturation : Unsaturated

Type of Ring System : Monocyclic

25:

Saturation : Unsaturated

10/700,278

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS	25	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

10/700,278

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 07:26:04 ON 08 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:26:12 ON 08 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 DEC 2006 HIGHEST RN 915067-95-7

DICTIONARY FILE UPDATES: 7 DEC 2006 HIGHEST RN 915067-95-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107002781.str



chain nodes :



10/700,278

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 19 20 21 22 23 24  
25 26 29 30  
ring nodes :  
17 33 34 35 36 37  
chain bonds :  
1-2 1-29 2-3 2-4 2-5 3-30 5-6 6-7 7-8 7-9 9-10 10-11 10-12 12-13  
12-14 14-15 15-16 15-18 16-17 18-19 18-20 19-26 20-21 21-22 22-23 22-24  
22-25  
ring bonds :  
17-33 17-37 33-34 34-35 35-36 36-37  
exact/norm bonds :  
2-4 2-5 5-6 7-8 7-9 9-10 10-11 12-13 12-14 14-15 18-19 20-21 21-22  
22-23 22-24 22-25  
exact bonds :  
1-2 1-29 2-3 3-30 6-7 10-12 15-16 15-18 16-17 18-20 19-26  
normalized bonds :  
17-33 17-37 33-34 34-35 35-36 36-37  
isolated ring systems :  
containing 17 :

Match level :

1:CLASS 2:CLASS 3:CLASS 4:Atom 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom  
18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom  
26:CLASS 29:CLASS 30:CLASS 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom

Generic attributes :

4:

Saturation : Unsaturated

Type of Ring System : Monocyclic

25:

Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 07:26:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 35 TO ITERATE

100.0% PROCESSED 35 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 346 TO 1054

PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

10/700,278

=> d scan

10/700,278


L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-(methylthio)- (9CI)


MF C40 H52 F N5 O5 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


10/700,278

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN L-Valinamide, N-[1-(4-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[4-aminophenyl)sulfonyl] (2-methylpropyl) amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI)

MF C37 H52 F N5 O5 S

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

10/700,278

=> s l1 sss ful

FULL SEARCH INITIATED 07:26:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 639 TO ITERATE

100.0% PROCESSED 639 ITERATIONS

32 ANSWERS

SEARCH TIME: 00.00.01

L3 32 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'CAPLUS' ENTERED AT 07:27:01 ON 08 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2006 VOL 145 ISS 25

FILE LAST UPDATED: 7 Dec 2006 (20061207/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 1 L3

=> d l4 bib hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:430693 CAPLUS  
DN 140:407115

TI Preparation of  $\alpha,\alpha$ -disubstituted benzylglycine derivatives as HIV protease inhibitors

IN Carini, David J.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004043355	A2	20040527	WO 2003-US35035	20031104
	WO 2004043355	A3	20040826		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2006128634	A1	20060615	US 2003-700278	20031103
	AU 2003291710	A1	20040603	AU 2003-291710	20031104
PRAI	US 2002-426223P	P	20021114		
	WO 2003-US35035	W	20031104		
OS	MARPAT 140:407115				
IT	689232-07-3P 689232-31-3P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of $\alpha,\alpha$ -disubstituted benzylglycine derivs. as HIV protease inhibitors)				
RN	689232-07-3 CAPLUS				
CN	L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



●<sub>x</sub> HCl


RN 689232-31-3 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[[ (4-aminophenyl) sulfonyl] (2-methylpropyl) amino]-2-hydroxy-1-

10/700,278

(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

IT 689232-08-4P 689232-09-5P 689232-10-8P  
689232-11-9P 689232-12-0P 689232-13-1P  
689232-14-2P 689232-15-3P 689232-16-4P  
689232-17-5P 689232-18-6P 689232-19-7P  
689232-20-0P 689232-21-1P 689232-23-3P  
689232-25-5P 689232-27-7P 689232-29-9P  
689232-33-5P 689232-35-7P 689232-37-9P  
689232-39-1P 689232-41-5P 689232-44-8P  
689232-46-0P 689232-48-2P 689232-50-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of  $\alpha,\alpha$ -disubstituted benzylglycine derivs. as HIV protease inhibitors)

RN 689232-08-4 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-09-5 CAPLUS

CN L-Valinamide, N-[1-(4-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-10-8 CAPLUS

CN L-Valinamide, N-[1-(3,5-difluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-  
[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-  
(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-11-9 CAPLUS

CN L-Valinamide, N-[1-(3-methoxyphenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-  
[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-  
(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OMe


RN 689232-12-0 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[4-  
aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-  
(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)



10/700,278

Absolute stereochemistry.




RN 689232-13-1 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● x HCl


PAGE 1-B



RN 689232-14-2 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/700,278

RN 689232-15-3 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-16-4 CAPLUS


CN L-Isoleucinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-17-5 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(1H-indazol-6-ylsulfonyl)(2-methylpropyl)amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-18-6 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-19-7 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-20-0 CAPLUS


CN L-Isoleucinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 689232-21-1 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)glycyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/700,278




RN 689232-23-3 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B




RN 689232-25-5 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)glycyl-N-[(1S,2R)-3-[[2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/700,278



RN 689232-27-7 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[ (3-amino-4-methylphenyl)sulfonyl] (2-methylpropyl) amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 689232-29-9 CAPLUS


CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl) (6-quinolinylsulfonyl) amino]-1-(phenylmethyl)propyl]-3-(methylthio)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10/700,278

RN 689232-33-5 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-35-7 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[(6-benzothiazolylsulfonyl)(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-37-9 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[[2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-39-1 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-β-alanyl-N-[(1S,2R)-3-[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/700,278



RN 689232-41-5 CAPLUS

CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-3-[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-44-8 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689232-46-0 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-hydroxy-3-[(2-methylpropyl)(6-quinolinylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



RN 689232-48-2 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[3-amino-4-methylphenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 689232-50-6 CAPLUS

CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-3-[[2-amino-6-benzothiazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






IT 689232-72-2P 689232-76-6P 689232-81-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of  $\alpha,\alpha$ -disubstituted benzylglycine derivs. as HIV  
 protease inhibitors)  
 RN 689232-72-2 CAPLUS  
 CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-  
 hydroxy-3-[(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-  
 (phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 689232-76-6 CAPLUS  
 CN L-Valinamide, N-[1-(3-fluorophenyl)-1-methylethyl]glycyl-N-[(1S,2R)-2-  
 hydroxy-3-[[4-methyl-3-nitrophenyl)sulfonyl](2-methylpropyl)amino]-1-  
 (phenylmethyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689232-81-3 CAPLUS  
 CN L-Valinamide, N-(1-methyl-1-phenylethyl)-D-alanyl-N-[(1S,2R)-2-hydroxy-3-  
 [(2-methylpropyl)[(4-nitrophenyl)sulfonyl]amino]-1-(phenylmethyl)propyl]-3-  
 methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/700,278



10/700,278

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.97

171.12

STN INTERNATIONAL LOGOFF AT 07:27:38 ON 08 DEC 2006